Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies

Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection. The ENRICH study examined BRII-179 as a priming therapy before administering elebsiran and PEG-IFNα. The trials are assessing the use of BRII-179, elebsiran, and PEG-IFNα to treat chronic hepatitis B virus infection. Credit: Jo Panuwat D / Shutterstock.com. Brii Biosciences (Brii Bio) has reported topline end-of-treatment (EOT) data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat…

Source: Clinical Trials Arena